Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Work In Process (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Work In Process for 15 consecutive years, with $11.8 million as the latest value for Q1 2026.

  • For Q1 2026, Work In Process rose 67.86% year-over-year to $11.8 million; the TTM value through Mar 2026 reached $11.8 million, up 67.86%, while the annual FY2025 figure was $13.7 million, 75.93% up from the prior year.
  • Work In Process hit $11.8 million in Q1 2026 for Corcept Therapeutics, down from $13.7 million in the prior quarter.
  • Across five years, Work In Process topped out at $14.2 million in Q3 2025 and bottomed at $6.7 million in Q2 2023.
  • Average Work In Process over 5 years is $9.7 million, with a median of $8.5 million recorded in 2023.
  • Year-over-year, Work In Process crashed 41.28% in 2023 and then surged 82.86% in 2025.
  • Corcept Therapeutics' Work In Process stood at $7.8 million in 2022, then increased by 5.19% to $8.2 million in 2023, then fell by 5.39% to $7.8 million in 2024, then skyrocketed by 75.93% to $13.7 million in 2025, then dropped by 13.82% to $11.8 million in 2026.
  • According to Business Quant data, Work In Process over the past three periods came in at $11.8 million, $13.7 million, and $14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.